Theresa Wingrove - 15 Sep 2023 Form 4 Insider Report for ImmunoGen, Inc.

Role
SVP OF REGULATORY AFFAIRS
Signature
/s/ Renee Lentini, Attorney-in-Fact
Issuer symbol
N/A
Transactions as of
15 Sep 2023
Net transactions value
-$2,567,617
Form type
4
Filing time
19 Sep 2023, 17:27:26 UTC
Previous filing
05 Jul 2023
Next filing
18 Oct 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction IMGN Common Stock Options Exercise $227,500 +50,000 +58% $4.55 136,156 15 Sep 2023 Direct
transaction IMGN Common Stock Options Exercise $101,669 +33,334 +24% $3.05* 169,490 15 Sep 2023 Direct
transaction IMGN Common Stock Options Exercise $67,895 +25,334 +15% $2.68* 194,824 15 Sep 2023 Direct
transaction IMGN Common Stock Sale $2,964,681 -192,013 -99% $15.44 2,811 15 Sep 2023 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction IMGN Stock Option (right to buy) Options Exercise $0 -50,000 -17% $0.000000 241,769 15 Sep 2023 Common Stock 50,000 $4.55 Direct F2
transaction IMGN Stock Option (right to buy) Options Exercise $0 -33,334 -67% $0.000000 16,666 15 Sep 2023 Common Stock 33,334 $3.05 Direct F3
transaction IMGN Stock Option (right to buy) Options Exercise $0 -25,334 -67% $0.000000 12,666 15 Sep 2023 Common Stock 25,334 $2.68 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.30 to $15.67, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within these ranges.
F2 On 2/7/2020, the reporting person was granted an option to purchase 333,450 shares of common stock. The option vests in installments upon the satisfaction of certain performance criteria. As of the transaction date, 75% of the awarded options are vested.
F3 This option was granted on 7/18/2016 and is fully vested as of the transaction date.
F4 This option was granted on 9/30/2016 and is fully vested as of the transaction date.